UTHR UNITED THERAPEUTICS Corp

Price (delayed)

$187.07

Market cap

$8.4B

P/E Ratio

17.71

Dividend/share

N/A

EPS

$10.56

Enterprise value

$8.26B

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and ...

Highlights
The equity has increased by 18% year-on-year and by 6% since the previous quarter
UNITED THERAPEUTICS's net income has increased by 16% QoQ and by 10% YoY
The stock's P/E is 22% above its last 4 quarters average of 14.5

Key stats

What are the main financial stats of UTHR
Market
Shares outstanding
44.89M
Market cap
$8.4B
Enterprise value
$8.26B
Valuations
Price to earnings (P/E)
17.71
Price to book (P/B)
2.3
Price to sales (P/S)
5.27
EV/EBIT
13.73
EV/EBITDA
12.68
EV/Sales
5.19
Earnings
Revenue
$1.59B
EBIT
$601.4M
EBITDA
$651.2M
Free cash flow
$562.5M
Per share
EPS
$10.56
Free cash flow per share
$12.56
Book value per share
$81.25
Revenue per share
$35.5
TBVPS
$107.15
Balance sheet
Total assets
$4.84B
Total liabilities
$1.21B
Debt
$800M
Equity
$3.64B
Working capital
$2.01B
Liquidity
Debt to equity
0.22
Current ratio
7.44
Quick ratio
6.88
Net debt/EBITDA
-0.22
Margins
EBITDA margin
40.9%
Gross margin
92.5%
Net margin
29.6%
Operating margin
27.9%
Efficiency
Return on assets
10.2%
Return on equity
13.7%
Return on invested capital
14.2%
Return on capital employed
13.3%
Return on sales
37.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
-0.28%
1 week
-4.25%
1 month
-8.42%
1 year
65.5%
YTD
23.24%
QTD
1.35%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$1.59B
Gross profit
$1.47B
Operating income
$443.8M
Net income
$470.9M
Gross margin
92.5%
Net margin
29.6%
The company's operating margin fell by 28% YoY but it rose by 16% QoQ
The operating income has grown by 23% from the previous quarter but it has contracted by 20% YoY
UNITED THERAPEUTICS's net income has increased by 16% QoQ and by 10% YoY
The company's gross profit rose by 12% YoY and by 5% QoQ

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
P/E
17.71
P/B
2.3
P/S
5.27
EV/EBIT
13.73
EV/EBITDA
12.68
EV/Sales
5.19
The stock's P/E is 22% above its last 4 quarters average of 14.5
The company's EPS rose by 16% QoQ and by 8% YoY
UTHR's price to book (P/B) is 21% higher than its last 4 quarters average of 1.9 and 10% higher than its 5-year quarterly average of 2.1
The equity has increased by 18% year-on-year and by 6% since the previous quarter
The stock's P/S is 55% above its 5-year quarterly average of 3.4 and 20% above its last 4 quarters average of 4.4
The company's revenue rose by 11% YoY and by 6% QoQ

Efficiency

How efficient is UNITED THERAPEUTICS business performance
The ROIC has grown by 13% from the previous quarter but it has contracted by 10% YoY
UNITED THERAPEUTICS's return on assets has increased by 12% QoQ but it has decreased by 3.8% YoY
The ROE has grown by 11% from the previous quarter but it has contracted by 8% YoY
The company's return on sales rose by 10% QoQ but it fell by 6% YoY

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The total assets has grown by 15% YoY and by 4.4% from the previous quarter
The current ratio has grown by 12% from the previous quarter
The debt is 78% less than the equity
The equity has increased by 18% year-on-year and by 6% since the previous quarter
UNITED THERAPEUTICS's debt to equity has decreased by 15% YoY and by 4.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.